Kanagal-Shamanna, Rashmi http://orcid.org/0000-0001-7829-5249
Montalban-Bravo, Guillermo
Katsonis, Panagiotis
Sasaki, Koji
Class, Caleb A. http://orcid.org/0000-0003-3130-3613
Jabbour, Elias
Sallman, David http://orcid.org/0000-0003-0504-8233
Hunter, Anthony Michael
Benton, Christopher
Chien, Kelly S.
Luthra, Rajyalakshmi
Bueso-Ramos, Carlos E.
Kadia, Tapan http://orcid.org/0000-0002-9892-9832
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Al Ali, Najla H
Short, Nicholas http://orcid.org/0000-0002-2983-2738
Daver, Naval http://orcid.org/0000-0001-7103-373X
Routbort, Mark J.
Khoury, Joseph D. http://orcid.org/0000-0003-2621-3584
Patel, Keyur http://orcid.org/0000-0001-5081-2427
Ganan-Gomez, Irene
Wei, Yue
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Ravandi, Farhad
Do, Kim-Anh
Soltysiak, Kelly A.
Lichtarge, Olivier
Medeiros, L. Jeffrey
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (R01-GM066099, R01-AG061105, R01-GM066099, R01-AG061105)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
UT | University of Texas MD Anderson Cancer Center (MDS/AML Moon Shot)
Article History
Received: 14 December 2020
Revised: 16 February 2021
Accepted: 19 February 2021
First Online: 6 March 2021
Conflict of interest
: K.S.: This author declares an advisory role with Pfizer Japan, Novartis, and Daiichi-Sanyo. E.J.: This author declares research support from and consultancy with AbbVie, Adaptive Biotechnologies, Amgen, Brisol Myers Squibb, Genentech, Pfizer, and Takeda. T.K.: This author reports honoraria from Novartis and Agios; grants and honoraria from Pfizer, AbbVie, Genentech, and Jazz Pharmaceuticals; and research grants from Bristol Myers Squibb, Amgen, AstraZeneca, Celgene, Incyte, and Ascentage. M.A.: This author declares research grants and a consultancy with Daiichi-Sanyo; consultancy with Jazz Pharmaceuticals, Celgene, Amgen, and AstraZeneca; equity ownership with Reata, Aptose, Eutropics, Senti Bio, Oncoceutics, and Oncolyze; and an advisory role with the Center for Drug Research and Development, Cancer UK, the Leukemia and Lymphoma Society, and Bioline. G.B.: This author declares research support from Oncoceutics, Xbiotech USA, Arvinas, Polaris, AstraZeneca, Bristol Myers Squibb, Cyclacel, GlaxoSmithKline, Janssen, Incyte, AbbVie, and Novartis; personal fees from Argenx, PTC Therapeutics, BioTheryX, Nkarta, Inc., Treadwell Therapeutics, and Curio Science; and personal fees and research support from FTC Therapeutics and BioLine Rx. H.K.: This author declares research support and an advisory role with Actinium, and research support from AbbVie, Agio, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. G.G.-M.: This author declares research support and an advisory role with Amphivena, Astex, and Celgene, and research support from AbbVie, H3 Biomedicine, Helsin, Onconova, Merck, and Novartis. The remaining authors declare no competing interests.